Bangladesh's Beximco enters COVID-19 vaccine deal with India's Serum Institute


Content Team
Image Credit: shortpedia

One of Bangladesh's largest drugmakers, Beximco Pharmaceuticals, has announced that it will invest in the Serum Institute of India (SII) for the development of a coronavirus vaccine. The deal is aimed at ensuring that Bangladesh has access to the vaccine. SII is the largest vaccine manufacturer and is conducting trials for three potential coronavirus vaccines, including the Oxford University-AstraZeneca's AZD1222 vaccine.